Board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2026, reporting a 174% YoY surge in Q4 standalone PAT to ₹263.84 million.
Recommended a dividend of ₹11 per equity share (110%) for FY26, subject to shareholder approval at the ensuing AGM.
Re-appointed Ms. Priya Gandhi as Executive Director for a 3-year term effective 28 October 2026, subject to member approval.
Divested 43.81% stake in subsidiary Texas Lifescience Private Limited on 27 March 2026, ceasing its subsidiary status.